New Neupogen Formula More Temperature Stable

Oncology NEWS InternationalOncology NEWS International Vol 6 No 5
Volume 6
Issue 5

THOUSAND OAKS, Calif--A new formulation of Neupogen (filgrastim or G-CSF) that contains sorbitol instead of mannitol is now available from Amgen.

THOUSAND OAKS, Calif--A new formulation of Neupogen (filgrastim or G-CSF)that contains sorbitol instead of mannitol is now available from Amgen.

The new formulation has the same clinical safety and efficacy profileas the mannitol-containing version, but offers additional flexibility withrespect to storage parameters.

Sorbitol-containing Neupogen will remain stable even if exposed to freezingtemperatures, as might occur in transit. The recommended storage temperaturewill continue to be 2° to 8° C. However, the gel tray insulationand freeze watch indicators required with mannitol-containing Neupogenwill be eliminated, allowing for smaller packaging and reduced need forrefrigerator inventory space.

Related Videos
Experts on multiple myeloma
Experts on multiple myeloma
An expert from Weill Cornell Medicine highlights key clinical data indicating the benefits of radium-223 in the treatment of patients with metastatic castration-resistant prostate cancer.
Experts on GVHD with a patient
Experts on breast cancer
Experts on GVHD with a patient
Experts on breast cancer
The risk of radionuclide exposure to the public reflects one reason urologists need to collaborate with radiation oncologists when administering radiopharmaceuticals to patients with prostate cancer.
Switching out beta emitters for alpha emitters, including radium-223, is one way to improve radiopharmaceutical treatment of prostate cancer, according to an expert from Weill Cornell Medicine.
Data demonstrate the feasibility of automated glomerular filtration rate prediction to decide between partial nephrectomy and radical nephrectomy in kidney cancer, according to an expert from the Cleveland Clinic.
Related Content